These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 31745840)

  • 1. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
    Borghi C; Palazzuoli A; Landolfo M; Cosentino E
    Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uric acid lowering therapy in cardiovascular diseases.
    Volterrani M; Iellamo F; Sposato B; Romeo F
    Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gout and cardiovascular risk].
    Němec P
    Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
    Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Safety of Urate Lowering Therapies.
    Kang EH; Kim SC
    Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum uric acid and the risk of cardiovascular and renal disease.
    Borghi C; Rosei EA; Bardin T; Dawson J; Dominiczak A; Kielstein JT; Manolis AJ; Perez-Ruiz F; Mancia G
    J Hypertens; 2015 Sep; 33(9):1729-41; discussion 1741. PubMed ID: 26136207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
    Kamatani N; Hosoya T
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
    [No Abstract]   [Full Text] [Related]  

  • 9. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gout and hyperuricemia.
    Chilappa CS; Aronow WS; Shapiro D; Sperber K; Patel U; Ash JY
    Compr Ther; 2010; 36():3-13. PubMed ID: 21229813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
    Bove M; Cicero AF; Veronesi M; Borghi C
    Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of serum uric acid on blood-pressure lowering treatment.
    Grassi G
    Curr Med Res Opin; 2017 Nov; 33(sup3):15-19. PubMed ID: 28952389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why focus on uric acid?
    Johnson RJ
    Curr Med Res Opin; 2015; 31 Suppl 2():3-7. PubMed ID: 26414730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
    Bove M; Cicero AFG; Borghi C
    Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
    Liu S; Perez-Ruiz F; Miner JN
    Joint Bone Spine; 2017 Mar; 84(2):183-188. PubMed ID: 27324603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How should we manage asymptomatic hyperuricemia?
    Chalès G
    Joint Bone Spine; 2019 Jul; 86(4):437-443. PubMed ID: 30316974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.